Immatics (IMTX) Income from Non-Controlling Interests (2021)
Immatics recorded quarterly Income from Non-Controlling Interests of -$33.6 million in Q2 2021.
Immatics' Income from Non-Controlling Interests history runs 1 years deep, the most recent figure standing at -$33.6 million for Q2 2021.
- In Q2 2021, Income from Non-Controlling Interests changed N/A year-over-year to -$33.6 million; the TTM figure through Jun 2021 stood at -$33.6 million (changed N/A YoY), while the FY2020 annual figure was -$269.8 million, down 649.64% from the prior year.
- Income from Non-Controlling Interests came in at -$33.6 million for Q2 2021 at Immatics.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$33.6 million in Q2 2021 to a low of -$33.6 million in Q2 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -33.64 Mn |